Smart Money Bets on Value | Predictions for 2025
Kimberly Westrich, M.A., chief strategy officer of National Pharmaceutical Council, shares her prediction for 2025.
My big prediction for 2025 is that value will play an increasingly important role in healthcare conversations. One place this will play out is in conversations about the Medicare Prescription Drug Negotiation Program. They will center not only around the unintended consequences of the program for patients but also about whether CMS is thinking about value as [it implements] the program and particularly as CMS releases the concise justifications for the first round of set prices.
Westrich
What evidence they say they considered may impact the incentives for generating value-related, real-world evidence in the future. Another area is that researchers will continue to explore and develop alternative methods that seek to better incorporate the full spectrum of value.
Finally, employers will continue to consider value as they select pharmacy benefits. Data from this year show that those with value-based formularies saved three times as much as those with rebate-based agreements.
The Global Impact of Underfunding Women’s Health
February 20th 2025Bias and stigma are to blame for the way women’s health research has fallen behind, according to Monica Christmas, M.D., director of UChicago Medicine’s menopause program and the Center for Women's Integrated Health and Valentina Sartori, Ph.D., the leader of the McKinsey Health Institute's Life Sciences Practice in Europe.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Solid Biosciences Reports Positive Data from DMD Gene Therapy Trial
February 19th 2025Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively to muscle cells.
Read More
